Categories: News

Aquarius Surgical Technologies Announces Share Issuance

TORONTO, ON / ACCESSWIRE / March 25, 2022 / Aquarius Surgical Technologies Inc. (CSE:ASTI) announces that it has issued 100,000 shares to each of four non-executive directors and to corporate officers, in compensation for services, for a total of 600,000 shares. All shares were issued at a stated price of $0.065 each. The shares were issued pursuant to the prospectus exemption contained in NI 45-106 s. 2.24 and are not subject to any restrictive hold period.

About Aquarius Surgical Technologies Inc.

Aquarius Surgical Technologies is a provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions also include clinical education, service, support and maintenance. ASTI is focused on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies and reducing total operational costs.

For more information, please contact:

Gary Van Nest, co-CEO gary@sinaltainvestments.com
Lorne MacFarlance, CFO lornemac@eastlink.ca ; 902-496-7594

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Aquarius Surgical Technologies Inc.

View source version on accesswire.com:
https://www.accesswire.com/694673/Aquarius-Surgical-Technologies-Announces-Share-Issuance

Staff

Recent Posts

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…

9 hours ago

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…

12 hours ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…

12 hours ago

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

12 hours ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…

12 hours ago